Tony Hagen


Novel Agents, Earlier Diagnosis Driving Survival Gains in CLL

January 03, 2019

The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis, said Richard Furman, MD, director of the Weill Cornell Medicine CLL Research Center, at the 36th Annual CFS®.

Shared Decision Making Key in Choosing Adjuvant Treatments for Melanoma

November 10, 2018

The fast pace of development in the immunotherapy and targeted therapy space has outstripped the availability of head-to-head comparative data for adjuvant melanoma treatment. Therefore, Hussein Tawbi, MD, PhD, recommended for healthcare professionals to communicate the relative merits and risks of both options to patients and making a shared decision.

Palbociclib Combo Effective in Frontline Treatment of ER+, HER2- Postmenopausal Metastatic Breast Cancer

March 10, 2018

Palbociclib (Ibrance), a CDK 4/6 inhibitor, demonstrated significant efficacy in combination with the aromatase inhibitor letrozole (Femara) in the frontline setting of estrogen receptor (ER)-positive, HER2-negative, postmenopausal metastatic breast cancer in phase III PALOMA-2 study.

CAR T-cell Therapy Introduced With $475,000 Price Tag

August 31, 2017

Tisagenlecleucel (Kymriah), Novartis' newly approved CAR T-cell therapy, will be put on the market with a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists and that Novartis characterized as well below a price level that could be justified on cost.

ASCO Calls for Alignment of Drug Costs and Values

July 21, 2017

“If you locked everybody in a room for a week, I think we could come up with something that everybody would be comfortable with,” said Blase Polite, MD, a co-author of the statement, and immediate past chair of ASCO’s government relations committee.